CADTH | Evidence Driven
CADTH | Evidence Driven

eltrombopag

Details

Files
Generic Name:
eltrombopag
Project Status:
Active
Therapeutic Area:
Severe Aplastic Anemia (SAA)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0777-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
N/A
Indications:
For the treatment of adult patients with severe aplastic anemia (SAA).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openApril 17, 2023
Call for patient/clinician input closedJune 12, 2023
Review initiatedMay 24, 2023
Clarification:

- Committee meeting date to be determined.

Expert committee meeting (initial)

Files

Eltrombopag for severe aplastic anaemia (SAA) View PDF

Related Content

Last Updated : May 25, 2023